Dianthus Therapeutics (DNTH)
Develops self-injected complement and dual-pathway therapies for severe autoimmune diseases.
Something off on this page? Send us feedback.
Develops subcutaneous autoimmune therapies led by active-C1s antibody claseprubart for neuromuscular diseases, with dual-pathway fusion proteins for rheumatologic conditions. Revenue comes from licensing rather than product sales while the pipeline remains subject to clinical and regulatory approval.
Develops autoimmune therapies around selective immune-pathway inhibition and infrequent subcutaneous self-administration. Claseprubart, an active-C1s monoclonal antibody, is in late-stage trials for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, alongside a mid-stage trial in multifocal motor neuropathy. DNTH212 combines BDCA2 and BAFF/APRIL inhibition for Sjögren’s disease, systemic lupus erythematosus, and dermatomyositis, while preclinical DNTH312 combines active-C1s and BAFF/APRIL inhibition.
Runs a single U.S. operating segment from New York, using global studies and Greater China license partners. Its programs span neuromuscular and rheumatologic disease, with molecular engineering focused on longer half-lives and low-volume self-injection. No candidate is approved and no product sales have been generated; development depends on clinical results, regulatory clearance, licensed rights, and third-party manufacturers.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | H.C. Wainwright | Reiterate | Buy | $130 | $158 | |
| Aug 5, 2026 | Wedbush | Reiterate | Outperform | $55 | $122 | |
| Aug 5, 2026 | Raymond James | Reiterate | Strong Buy | $125 | $131 | |
| Jun 10, 2026 | Jefferies | Target | $98 | $132 | ||
| May 11, 2026 | Evercore ISI | Target | $120 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $886.8M · Total debt $1.3M · Total assets $1.21B · Shareholders' equity $1.17B
- Revenue
- $761.0K
- Operating income
- −$61.5M
- Net income
- −$50.2M
No dividends on record.
| Institutions277 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 115.36% | 64.52M shares | |
| Insiders3 holders · as of Aug 14, 2026 | 0.19% | 106.1K shares | |
| Adds to | 115.55% |
55.93M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 115.55%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 14.66% | 8.20M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.37% | 4.12M | 13Fas of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 6.95% | 3.89M | 13Fas of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 5.77% | 3.23M | 13Fas of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 5.00% | 2.80M | 13Gfiled May 15, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Simon Read | director | −2,778 | $117.55 |
| Aug 10, 2026 | Anne McGeorge | director | −7,750 | $109.01 |
| Aug 10, 2026 | Adam M. Veness | officer: SVP, General Counsel and Sec. | −16,167 | $110.38 |
| Aug 7, 2026 | Adam M. Veness | officer: SVP, General Counsel and Sec. | −3,833 | $110.70 |
| Aug 10, 2026 | Simon Read | director | −2,777 | $109.55 |
- argenx (ADR)
Vyvgart (efgartigimod) FcRn antagonist approved in gMG and CIDP; $4.2B in 2025.
- AstraZeneca (ADR)
Alexion complement franchise — Soliris/Ultomiris (C5, IV-only) approved in gMG.
- Sanofi (ADR)
Anti-C1s mAb riliprubart; CIDP Phase 3 MOBILIZE stopped for futility Jun 2026.
- Annexon
Anti-C1q mAb tanruprubart; GBS Phase 3 complete; EMA MAA filed Jan 2026.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics | $106.23 | −0.08% | $5.94B | — | — | 3,121.0 | +294.3% |
| argenx (ADR) | $1,060.17 | +0.44% | $65.63B | 38.5 | — | 12.5 | — |
| AstraZeneca (ADR) | $164.21 | +1.58% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Sanofi (ADR) | $44.77 | +0.69% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Annexon | $4.96 | +0.41% | $807.7M | — | — | — | — |
| Median | 38.5 | 15.2 | 4.1 | +8.8% |